Generated by AI
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing and commercializing topical treatments for skin diseases. Its current portfolio includes approved products for acne vulgaris and papulopustular rosacea, alongside a pipeline of dermatology candidates aimed at severe and rare skin conditions such as Gorlin syndrome and other hyperkeratosis-related disorders. The company also works on generic topical drug products and uses its proprietary silica-based microencapsulation technology to improve the stability, tolerability, and delivery of active ingredients. Sol-Gel Technologies Ltd. serves healthcare markets in Israel and internationally, with its products and development programs positioned within medical dermatology and specialty pharmaceuticals. Founded in 1997 and headquartered in Ness Ziona, Israel, the company operates as a focused participant in the treatment of skin disorders through targeted topical therapies.
Website7 Golda Meir Street
Ness Ziona, 7403650
Israel
The latest articles about SLGL.
Summary of Mar 24's posts. Generated by AI.
Summary of Mar 24's posts. Generated by AI.
Detailed price information for Sol-Gel Technologies Ltd (SLGL-Q) from The Globe and Mail including charting and trades.
Summary of Mar 24's posts. Generated by AI.
Summary of Mar 24's posts. Generated by AI.
Investors talking about SLGL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.